Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 4549.

https://doi.org/10.1182/blood-2024-205800

Published: 2024

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 6077–6079.

https://doi.org/10.1182/blood-2022-167365

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study

Alberto Lázaro García, Marta González Rodríguez, Edwin Uriel Suárez Merchán, Gonzalo Castellanos Arias, Alicia de las Heras Moreno, María Pilar Llamas Sillero, Eduardo García Romo, Antonio Noguera Tejedor, Laura Solán Blanco, Antonio Herrero, Juan Manuel Alonso Dominguez

Blood (2022) 140 (Supplement 1): 8094–8095.

https://doi.org/10.1182/blood-2022-165525

Published: 2022

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Blood (2021) 138 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2021-152353

Published: 2021

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Bruno Paiva, PhD, María Belén Vidriales, Maria Desamparados Sampere Talens, Fabian Tarin, Enrique Colado, Celina Benavente, María Teresa Cedena, MD, Joaquin Sanchez, MD, Teresa Caballero-Velázquez, MD PhD, Lourdes Cordon, David Martínez-Cuadron, MD, Teresa Bernal del Castillo, MD PhD, Carmen Botella, Sofia Grille, MDPhD, Josefina Serrano, MD, Carlos Rodriguez, Jesús Lorenzo Algarra, Juan Manuel Alonso Dominguez, MD PhD MSc, Maria Luz Amigo, MD, Manuel BARRIOS García, MDPhD, Raimundo García-Boyero, MD, Mercedes Colorado, MD, Jaime Perez De Oteyza, MDPhD, Manuel Perez Encinas, MD, Lissette Del Pilar Costilla, MD, Maria Jose Sayas, Olga Pérez-López, Marcos González, Jose A. Perez-Simon, MD PhD, Joaquin Martinez-Lopez, MD PhD, Claudia Lucia Sossa, Alberto Orfao, MD PhD, Jesús F. San-Miguel, Miguel Sanz, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-134349

Published: 2020

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Blood (2019) 134 (Supplement_1): 4171.

https://doi.org/10.1182/blood-2019-126980

Published: 2019

Journal Articles

Study of the Clinical Significance of the Length of FLT3-ITD in Acute Myeloid Leukemia Patients

Tamara Castaño, MD, Rosa Ayala, MD PhD, Maria Pilar Llamas Sillero, Joaquin Martinez Lopez, MD, Rocio N Salgado, PhD, Mireia Atance, Jose Luiz Lopez Lorenzo, MD, Jose F. Tomas, MD PhD, Carlos Blas, MD, Juan Manuel Alonso Dominguez, MD PhD MSc

Blood (2018) 132 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2018-99-115164

Published: 2018

Journal Articles

Inhibition of the Hedgehog Pathway Decreases the Quiescent CD34+CD38- Population in Acute Myeloid Leukemia

Alicia Arenas, Daniel Lainez, Cristina Serrano del Castillo, MD, Rocio N Salgado, PhD, Carlos Blas, MD, Mireia Atance, Raul Cordoba, MD PhD, Pilar Llamas, MD PhD, Juan Manuel Alonso Dominguez, MD PhD MSc

Blood (2018) 132 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2018-99-118636

Published: 2018

Journal Articles

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Juan Manuel Alonso Dominguez, MD PhD MSc, Rodrigo Iñiguez Garcia, MD, Susana Olmedillas, PhD, Rocio N Salgado, PhD, Tamara Castaño, MD, Carlos Blas, MD, Diego Velasco Rodrgiguez, MD PhD, Gala Vega, MD, Jose Luis Lopez Lorenzo, MD, Pilar Giraldo, PhD, Joaquin Martinez Lopez, MD PhD, Pilar Llamas, MDPhD, Mireia Atance, Arantxa Garcías Raso

Blood (2017) 130 (Supplement 1): 2891.

https://doi.org/10.1182/blood.V130.Suppl_1.2891.2891

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

Juan Manuel Alonso Dominguez, MD PhD MSc, Alicia Arenas, PhD, Pilar Llamas, MDPhD, Diego Velasco, Aránzazu García-Raso, PhD, Jose Luis Lopez Lorenzo, MD, Mireia Atance, Rocio N Salgado, PhD, Joaquin Martinez Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 5245.

https://doi.org/10.1182/blood.V130.Suppl_1.5245.5245

Published: 2017

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

NARROW

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Study of the Clinical Significance of the Length of FLT3-ITD in Acute Myeloid Leukemia Patients

Inhibition of the Hedgehog Pathway Decreases the Quiescent CD34+CD38- Population in Acute Myeloid Leukemia

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only